Evogene, Bayer end herbicide project; assets revert

Evogene Ltd. reports that its subsidiary Ag Plenus Ltd. (AgPlenus) and Bayer AG have decided to discontinue their joint herbicide development project, effective May 18, 2026, after determining the target protein did not meet required product criteria.

Rhea-AI Filing Summary

Evogene Ltd. reports that its subsidiary Ag Plenus Ltd. (AgPlenus) and Bayer AG have decided to discontinue their joint herbicide development project, effective May 18, 2026, after determining the target protein did not meet required product criteria.

All assets previously licensed to Bayer under the collaboration, including the APTH1 protein target and associated active molecules, will revert to AgPlenus. The report is also incorporated by reference into Evogene’s effective Form F-3 and multiple Form S-8 registration statements.

Key Terms

herbicide development project, target protein, APTH1 protein target, Form F-3, +1 more

5 terms

herbicide development project technical

"decided to discontinue their herbicide development project"

target protein technical

"following determination that the target protein did not meet the required product criteria"

APTH1 protein target technical

"including the APTH1 protein target and associated active molecules, will revert to AgPlenus"

Form F-3 regulatory

"incorporated by reference into the registration statements on Form F-3"

Form F-3 is a U.S. securities filing that lets eligible foreign companies pre-register and then quickly sell shares or other securities to raise money, because they already meet ongoing reporting and size tests. For investors it signals that the company is up-to-date with regulatory disclosure and has an efficient way to issue new securities — similar to a pre-approved credit line — which can mean faster capital raises but also potential dilution of existing holdings.

Form S-8 regulatory

"and on Form S-8 (SEC File Nos. 333-193788, 333-201443...)"

A Form S-8 is a U.S. Securities and Exchange Commission registration that lets a public company set aside shares for employee benefit plans and stock-based compensation. Think of it as opening a dedicated account that authorizes the company to issue or reserve stock for workers and directors; it matters to investors because it enables share dilution when those awards are granted or exercised and signals how management is compensated and incentivized.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evogene (EVGN) announce regarding its collaboration with Bayer?

Evogene announced that its subsidiary AgPlenus and Bayer agreed to discontinue their herbicide development project. The decision followed a determination that the target protein failed to meet required product criteria, ending the collaboration effective May 18, 2026.

Why was the Evogene–Bayer herbicide project discontinued?

The herbicide project was discontinued because the target protein did not meet the required product criteria. After this determination, Evogene’s subsidiary AgPlenus and Bayer mutually decided to terminate the collaboration, with the termination effective as of May 18, 2026.

What happens to the APTH1 protein target after Evogene and Bayer ended the project?

After termination, all assets licensed to Bayer revert to AgPlenus, including the APTH1 protein target and associated active molecules. This means AgPlenus regains full control over these discovery assets previously shared under the herbicide development collaboration.

When does the termination of Evogene and Bayer’s herbicide collaboration take effect?

The termination of the herbicide development collaboration between AgPlenus, Evogene’s subsidiary, and Bayer takes effect on May 18, 2026. From that date, the parties cease project activities and licensed assets under the collaboration revert to AgPlenus.

How is this Evogene (EVGN) 6-K used in the company’s registration statements?

The Form 6-K is incorporated by reference into Evogene’s Form F-3 and several Form S-8 registration statements. This means the information becomes part of those SEC registration documents from the date of submission, unless later filings supersede it.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/18/2026 - 04:01 PM Learn about SEC filing dates

UNITED STATES 

 SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number: 001-36187

EVOGENE LTD.

  (Translation of Registrant’s Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒       Form 40-F ☐

CONTENTS

On May 18, 2026, Evogene Ltd. (“Evogene”) announced that its subsidiary Ag Plenus Ltd. (“AgPlenus”) and Bayer Ag (“Bayer”) have decided to discontinue their herbicide development project following determination that the target protein did not meet the required product criteria. The termination will enter into effect as of May 18, 2026. Under the terms of the termination, all assets licensed to Bayer under the collaboration, including the APTH1 protein target and associated active molecules, will revert to AgPlenus.

The content of this Form 6-K is incorporated by reference into the registration statements on Form F-3 (File No. 333-277565) and on Form S-8 8 (SEC File Nos. 333-193788, 333-201443, 333-203856, 333-259215, and 333-286197) of the Company, filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: May 18, 2026 EVOGENE LTD.
(Registrant)

By: /s/ Ofer Haviv
Ofer Haviv
Chief Executive Officer